Can systems biology approach help in finding more effective treatment for acute myeloid leukemia?

Systems and Synthetic Biology Pub Date : 2014-06-01 Epub Date: 2014-04-16 DOI:10.1007/s11693-014-9147-5

Anuradha Vaidya

{"title":"Can systems biology approach help in finding more effective treatment for acute myeloid leukemia?","authors":"Anuradha Vaidya","doi":"10.1007/s11693-014-9147-5","DOIUrl":null,"url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a hematological cancer comprising of cancer stem cells (CSCs) that are responsible for the disease progression, drug resistance and post treatment relapses. Advances in genomic technologies have identified AML as a genetically heterogenous disease with dysregulated gene expression networks. Furthermore, observation of intracellular signaling in individual CSCs by mass cytometry has demonstrated the dysregulation of the mitogen associated protein kinase (MAPK) pathways. It has been envisaged that the future treatment for AML would entail upon formulating individualized treatment plans leading to decreased drug related toxicities for patients. However the emerging role of signaling pathways as dynamic molecular switches influencing the cell cycle process, thereby leading to varying stages of cell differentiation, is making community rethink about the current strategies used for the treatment of AML. This commentary will focus on discovering novel biomarkers and identifying new therapeutic targets, to analyze and treat AML, on a platform enabled by systems biology approach. </p>","PeriodicalId":22161,"journal":{"name":"Systems and Synthetic Biology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11693-014-9147-5","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Systems and Synthetic Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11693-014-9147-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/4/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

Abstract

Acute myeloid leukemia (AML) is a hematological cancer comprising of cancer stem cells (CSCs) that are responsible for the disease progression, drug resistance and post treatment relapses. Advances in genomic technologies have identified AML as a genetically heterogenous disease with dysregulated gene expression networks. Furthermore, observation of intracellular signaling in individual CSCs by mass cytometry has demonstrated the dysregulation of the mitogen associated protein kinase (MAPK) pathways. It has been envisaged that the future treatment for AML would entail upon formulating individualized treatment plans leading to decreased drug related toxicities for patients. However the emerging role of signaling pathways as dynamic molecular switches influencing the cell cycle process, thereby leading to varying stages of cell differentiation, is making community rethink about the current strategies used for the treatment of AML. This commentary will focus on discovering novel biomarkers and identifying new therapeutic targets, to analyze and treat AML, on a platform enabled by systems biology approach.

查看原文本刊更多论文

系统生物学方法能帮助找到更有效的治疗急性髓系白血病的方法吗?

急性髓性白血病(AML)是一种由癌症干细胞(CSCs)组成的血液学癌症，它与疾病进展、耐药和治疗后复发有关。基因组技术的进步已经确定AML是一种基因表达网络失调的遗传异质性疾病。此外，通过流式细胞术观察单个CSCs的细胞内信号传导已经证实了丝裂原相关蛋白激酶(MAPK)通路的失调。据设想，未来AML的治疗将需要制定个性化的治疗计划，从而降低患者的药物相关毒性。然而，信号通路作为影响细胞周期过程的动态分子开关的新兴作用，从而导致细胞分化的不同阶段，正在使社区重新思考当前用于治疗AML的策略。本评论将侧重于发现新的生物标志物和确定新的治疗靶点，在系统生物学方法支持的平台上分析和治疗AML。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Systems and Synthetic Biology

自引率

0.00%

发文量